Retevmo (selpercatinib) for the Treatment of RET-Driven Cancers
RetevmoTM (selpercatinib) is the first therapy specifically indicated for the treatment of patients with advanced RET-driven lung and thyroid cancers. Credit: Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more